Inspection Record

Auro Pharmacies — FDA 483 Findings

US FDAInspected 2018-08-28Published 2024-01-17 9 findingsAseptic processing and sterility assuranceOther quality systemMaterial and supplier controlEquipment and facilityStability and storage

Inspectors Andrew K. HaackThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Aseptic processing and sterility assurance

Personnel conducted aseptic manipulations in an area that blocked the movement of first pass air around an open unit, either before or after it was filled with sterile product.

2Other quality system

JS0-5 classified areas were not certified under dynamic conditions.

3Material and supplier control

Each component is not tested for conformity with all appropriate written specifications fqr purity, strength, and quality.

4Equipment and facility

Buildings used in the manufacture, processing, packing, or holding o fa drug product do not have the suitable construction to facilitate cleaning, maintenance, and proper operations.

5Equipment and facility

Vermin was observed in an area immediately adjacent to your production area.

6Aseptic processing and sterility assurance

You did not make adequate product evaluation and take remedial action where actionable microbial contamination was found to be present in the ISO 5 classified aseptic processing area during aseptic production.

8Other quality system

You have not established appropriate Beyond Use Dates for your products.

9Aseptic processing and sterility assurance

Media fills were not performed that closely simulate aseptic production operations incorporating, as appropriate, worst-case activities and conditions that provide a challenge to aseptic operations.

About this record

Extracted automatically from the document US FDA published on 2024-01-17. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Other records for this company

Auro Pharmacies findings history — including this company's other documentsAll US FDA findings US FDA documents, 2024 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.